Assistant Professor
Obstetrics & Gynecology
Dr. Alpa M. Nick, MD
Alpa M. Nick is an expert in the field of Obstetrics & Gynecology. She went to Louisiana State University School of Medicine in Shreveport. Alpa Nick is also published. She has 79 publications published. The lastest publication: "Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.' She accepts Medicare.
Publications
- Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part I.
- Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations - Part II.
- Carcinoma of the Bartholin Gland: A Review of 33 Cases.
- A call for New Standard of Care In Perioperative Gynecologic Oncology Practice: Impact of enhanced recovery after surgery (ERAS) programs.
- Erythropoietin Stimulates Tumor Growth via EphB4.
- Small cell Carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
- Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian Cancer.
- Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian Cancer.
- A framework for a personalized surgical approach to ovarian Cancer.
- Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients.
- Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence.
- Position-related injury is uncommon in robotic gynecologic surgery.
- Differential platelet levels affect response to taxane-based therapy in ovarian Cancer.
- Significance of lymph node ratio in defining risk category in node-positive early stage Cervical cancer.
- Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian Cancer.
- Hematogenous metastasis of ovarian Cancer: rethinking mode of spread.
- Conversion from robotic surgery to laparotomy: A case-control study evaluating risk factors for conversion.
- Minimally invasive surgery for endometrial Cancer: Does operative start time impact surgical and oncologic outcomes?
- Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian Cancer.
- MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN Cancer.
- Notch3 Pathway Alterations in Ovarian Cancer.
- Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent Cervical cancer with distant metastases.
- Impact of cardiovascular comorbidity on ovarian Cancer mortality.
- Successful incorporation of robotic surgery into gynecologic oncology fellowship training.
- Incidence of trocar site herniation following robotic gynecologic surgery.
- Venous Thromboembolic Events in Minimally Invasive Gynecologic Surgery.
- Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.
- Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.
- Epigenetic analysis of the Notch superfamily in high-grade serous ovarian Cancer.
- Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies.
- Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors.
- Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging.
- Second-trimester intra-abdominal bowel dilation in fetuses with gastroschisis predicts neonatal bowel atresia.
- The effect of hormonal contraception on the adequacy of colposcopic examination of the cervix.
- Paraneoplastic thrombocytosis in ovarian Cancer.
- Fertility sparing surgery for treatment of early-stage Cervical cancer: Open vs. robotic radical trachelectomy.
- The impact of robotic surgery on gynecologic oncology.
- Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death.
- Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology.
- Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian Cancer.
- Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer.
- Rate of Port-Site Metastasis Is Uncommon in Patients Undergoing Robotic Surgery for Gynecological Malignancies.
- Functional roles of Src and Fgr in ovarian Carcinoma.
- Outcomes of patients undergoing radical hysterectomy for Cervical cancer of high-risk histological subtypes.
- Tramadol-induced flushing managed with aspirin premedication.
- Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial Cancer.
- Targeting aldehyde dehydrogenase Cancer stem cells in ovarian Cancer.
- Rate of Vaginal cuff separation following laparoscopic or robotic hysterectomy.
- Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery.
- Conservative surgery in early-stage Cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?
- Regulation of tumor angiogenesis by EZH2.
- Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian Carcinoma.
- Targeted gene silencing using RGD-labeled chitosan nanoparticles.
- Sustained small interfering RNA delivery by mesoporous silicon particles.
- Adrenergic modulation of focal adhesion kinase protects human ovarian Cancer cells from anoikis.
- EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial Carcinoma.
- Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian Cancer.
- c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian Cancer.
- Targeting pericytes with a PDGF-B aptamer in human ovarian Carcinoma models.
- Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian Cancer.
- Anti-angiogenic properties of metronomic topotecan in ovarian Carcinoma.
- EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian Carcinoma.
- Anti-angiogenesis therapy with bevacizumab for patients with Ovarian granulosa cell tumors.
- Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
- Dual targeting of EphA2 and FAK in ovarian Carcinoma.
- Estrous cycle modulates ovarian Carcinoma growth.
- Surgical stress promotes tumor growth in ovarian Carcinoma.
- Dicer, Drosha, and outcomes in patients with ovarian Cancer.
- Functional significance of VEGFR-2 on ovarian Cancer cells.
- Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian Cancer.
- Targeting aurora kinase with MK-0457 inhibits ovarian Cancer growth.
- The ROC ''n'' role of the multiplex assay for early detection of ovarian Cancer.
- Clinical and biological significance of tissue transglutaminase in ovarian Carcinoma.
- EphA2 overexpression promotes ovarian Cancer growth.
- Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian Carcinoma.
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory Cancers.
- Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
- Characteristics of 10-year survivors of high-grade serous ovarian Carcinoma.
Procedures Preformed
- Abdominal Hysterectomy With Robotic Assistance
- Colporrhaphy
- Colposcopy
- Dilation and Curettage
- View All
Conditions Treated
- Carcinoma in Situ
- Cervical Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Education
-
Vanderbilt University -
Louisiana State University School of Medicine in Shreveport
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1265589139 | |
| NPPES Provider LastName | NICK | |
| NPPES Provider FirstName | ALPA | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 170.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 10.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265589139 |
| Last Name Of The Provider | NICK |
| First Name Of The Provider | ALPA |
| View All |
Similar Doctors
|
Dr. Barry S. Siller, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Keith O. Reeves, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Katherine K. McKnight, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan L. Kaplan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Candice O. Perfetto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas W. Burke, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Geri-Lynn Fromm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aparna A. Kamat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Audra E. Timmins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriel E. Hoyos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Liz Y. Han, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Manju Monga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonny J. Stetson, MD
This Doctor is OpenDoctor Recommended.
|